Hansoh Pharmaceutical Group reported a 36% rise in first-half profit to 4.26 billion yuan ($633.90M) on Wednesday morning, driven by strong innovative drug sales. The result beat an HSBC Qianhai Securities forecast of 2.9 billion yuan, up from 3.13 billion yuan a year earlier. China's drugmakers are pushing licensing deals and new medicines as state bulk-buying programs squeeze traditional revenue streams.

Innovative Medicines Drive Growth